Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 5 Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Colonic Neoplasms 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Tooth, Impacted 1 Testicular Neoplasms 1 Smoldering Multiple Myeloma 1 Oropharyngeal Neoplasms 1 Neuroblastoma 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Melanoma 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Hepatoblastoma 1 Hematologic Neoplasms 1 Hemangioma, Cavernous, Central Nervous System 1 Hemangioma, Cavernous 1 Ganglioneuroblastoma 1 Fibrolamellar hepatocellular carcinoma 1 Esophageal Neoplasms 1 Epstein-Barr Virus Infections 1 Carcinoma, Renal Cell 1 Breast Carcinoma In Situ 1 Anus Neoplasms 1 Anal Canal Carcinoma 1

Interventions

Specimen Handling 5 Nivolumab 4 avelumab 3 Magnetic Resonance Spectroscopy 3 pembrolizumab 2 cabozantinib 2 atezolizumab 2 Ipilimumab 2 Immunoglobulin G 2 Disulfides 2 CTLA-4 Antigen 2 Biopsy 2 tremelimumab 1 tocilizumab 1 relatlimab 1 guadecitabine 1 eribulin 1 erdafitinib 1 enfortumab vedotin 1 durvalumab 1 Watchful Waiting 1 Propranolol 1 Observation 1 Gemcitabine 1 Doxorubicin 1 Cystoscopy 1 Contrast Media 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Ureteral Neoplasms × Watchful Waiting × Clear all

NCT03244384 2026-05-29

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡